
"Now, with the speed and collaboration features of Treatment Pathways, healthcare researchers can work faster and smarter," said Bill Marder, PhD, senior vice president for research services at Thomson Reuters.
"This tool will transform how studies are conducted, because it significantly improves efficiency and provides fast answers to critical research questions.
"Thomson Reuters has extensive experience creating analytically-ready databases. Now, we are leading the way in developing innovative tools and processes to improve research using large datasets," Marder said. "Treatment Pathways provides broader and faster access to data than ever before."
The MarketScan Research Databases contain de-identified healthcare claims data reflecting the real-world clinical care of more than 148 million patients--the largest proprietary dataset of its kind. Academic, industry, and government researchers have used this information for decades to analyze the efficacy of medical treatments, the cost of care, prescription drug utilization patterns, and other important healthcare issues. MarketScan Treatment Pathways enables researchers to explore patterns in these rich databases in new ways.
For more information, please e-mail healthcare.pharma@thomsonreuters.com.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.
No comments:
Post a Comment